Catalent, Inc. recently stated on Twitter that its plant in Bloomington, Indiana received emergency use authorization from the Food and Drug Administration (FDA) to produce and ship Johnson & Johnson COVID-19 vaccine doses. While the FDA refused to comment on the authorization, Mike Riley, Catalent’s regional biologics president for North America, said the authorization will allow the company to "produce and ship millions of doses."
To ramp up production and meet its goal of supplying 20 million vaccine doses to the United States by the end of March, Johnson & Johnson contracted with Catalent and Emergent BioSolutions, Inc. to help produce its COVID-19 vaccine. While Emergent is tasked with manufacturing the active ingredient in Johnson & Johnson’s vaccine, Catalent serves as a “fill-finish” facility that bottles the vaccine doses. The FDA authorized the Johnson & Johnson one-shot vaccine last month, but the authorization applied only to the drug company’s production facility in the Netherlands and a small fill-and-finish plant in the United States.
Click here to see more details.
Click here for our COVID-19 vaccines updates.